Managers / Q1 2026
Green Alpha Advisors, LLC
CIK 0001439207 · 136 2ND AVENUE, UNIT D, NIWOT, CO, 80544 · 3039937856
Summary
Green Alpha Advisors, LLC reported $102M in U.S.-listed holdings across 107 positions for Q1 2026.
Its largest position, LRCX, represents 6.0% of the portfolio.
Compared with Q4 2025, the fund opened 1 new position and exited 9.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 90.9% · $92M
- Other · 8.3% · $8M
- ETP · 0.4% · $439,417
- ADR · 0.4% · $388,654
Quarter-over-Quarter Changes full breakdown →
vs Q4 2025 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| TWSTTWIST BIOSCIENCE CORP | NEW | +5.3K | 5.3K | +$251,999 | $251,999 |
| AZTAAZENTA INC | SOLD OUT | −9.2K | 0 | −$307,223 | $0 |
| EXKEXACT SCIENCES CORP | SOLD OUT | −2.9K | 0 | −$293,305 | $0 |
| GTLBGITLAB INC | SOLD OUT | −7.4K | 0 | −$278,998 | $0 |
| ISRGINTUITIVE SURGICAL INC | SOLD OUT | −466 | 0 | −$263,924 | $0 |
| YETIYETI HLDGS INC | SOLD OUT | −5.8K | 0 | −$255,435 | $0 |
| BEAMBEAM THERAPEUTICS INC | SOLD OUT | −8.5K | 0 | −$236,091 | $0 |
| TXG10X GENOMICS INC | SOLD OUT | −10.2K | 0 | −$165,595 | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2026
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $102M | 107 | Apr 7, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $109M | 115 | Jan 7, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $104M | 102 | Oct 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $105M | 109 | Aug 1, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $94M | 112 | Apr 9, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $125M | 147 | Jan 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $127M | 141 | Oct 7, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $124M | 138 | Aug 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $138M | 142 | Apr 10, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $139M | 151 | Jan 5, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $130M | 156 | Oct 10, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $152M | 153 | Jul 6, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $143M | 150 | Apr 6, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $120M | 144 | Jan 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $118M | 141 | Oct 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $435M | 149 | Jul 8, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $148M | 136 | Apr 19, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $148M | 124 | Jan 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $145M | 126 | Oct 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $147M | 127 | Jul 22, 2021 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.